Table 3.
Likelihood of red blood cell transfusion in chemotherapy-associated anemia patients: Aarhus and North Jutland, Denmark (1998–2003)
| Crude likelihood (RR) for transfusion | Likelihood (RR) for transfusion adjusted for tumor typea | Likelihood (RR) for transfusion adjusted for tumor siteb | |
|---|---|---|---|
| RR (95% CI) | RR (95% CI) | RR (95% CI) | |
| Gender | |||
| Female | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Male | 1.21 (1.04–1.40) | 0.94 (0.81–1.09) | 0.90 (0.77–1.05) |
| Age (years) | |||
| 0–19 | 2.61 (2.00–3.40) | 2.08 (1.58–2.73) | 1.89 (1.44–2.49) |
| 20–49 | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| 50–59 | 1.02 (0.81–1.27) | 0.99 (0.79–1.25) | 0.98 (0.78–1.23) |
| 60–69 | 1.11 (0.89–1.38) | 1.04 (0.83–1.30) | 1.01 (0.81–1.27) |
| 70–79 | 1.21 (0.95–1.54) | 1.06 (0.83–1.35) | 1.02 (0.80–1.31) |
| 80+ | 1.23 (0.81–1.85) | 0.91 (0.60–1.38) | 0.87 (0.57–1.31) |
| Tumor spread | |||
| Stage I | 0.42 (0.16–1.12) | 0.64 (0.23–1.74) | 0.48 (0.17–1.33) |
| Stage II | 0.42 (0.30–0.57) | 0.47 (0.34–0.65) | 0.52 (0.37–0.72) |
| Stage III | 0.55 (0.45–0.67) | 0.66 (0.54–0.81) | 0.68 (0.55–0.83) |
| Stage IV | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| Unspecified | 1.27 (1.07–1.51) | 0.93 (0.76–1.15) | 0.97 (0.78–1.19) |
| Cancer type | |||
| Hematologic cancers | 1.00 (reference) | 1.00 (reference) | |
| Solid tumors | 0.56 (0.48–0.64) | 0.87 (0.71–1.07) | |
| Cancer site | |||
| Hematologic cancers | 1.00 (reference) | 1.00 (reference) | |
| Colorectal and gastrointestinal | 0.45 (0.35–0.58) | 0.72 (0.52–1.00) | |
| Gynecologic, urinary tract, and prostate | 0.63 (0.50–0.79) | 1.01 (0.74–1.37) | |
| Lung | 0.78 (0.64–0.94) | 0.93 (0.73–1.17) | |
| Breast | 0.18 (0.12–0.28) | 0.34 (0.21–0.55) | |
| Other | 0.78 (0.56–1.07) | 1.04 (0.73–1.50) | |
Notes:
a
Adjusting for tumor type in two groups: hematologic cancers and solid tumors;
b
Adjusting for tumor site: hematologic cancers; colorectal and gastrointestinal; gynecologic, urinary tract, and prostate; lung; breast; and other, which included endocrinal glands, bone, melanoma of skin, connective tissue and unspecified male genital organs, testis, eye, brain and nervous system, thyroid, metastases, nonmelanoma of skin, and peritoneum and unspecified connective tissue.
Abbreviations: CI, confidence interval; RR, relative risk.